1 ratings / 5 average

Statin-Induced Myopathy 
and its Management

Catherine Buettner, MD, MPH1,2, Martin A Kriegel, MD1,2,3, Rebecca E Wells, MD, MPH1,2, and Jim S Wu, MD1,2

Statins (3-hydroxy-3-methylglutaryl-coenzyme A [HMG-CoA] reductase inhibitors) are the most efficacious medications for lowering cholesterol [1]. They are usually well tolerated, with few serious side-effects [2]. However, muscle symptoms and/or creatine kinase (CK) elevations are considered the most common and important adverse effects [3] and may lead to discontinuation of these beneficial medications, which have been proven to significantly reduce cardiovascular (CV) events as well as CV and all-cause mortality rates [4–6]. Muscle-related side-effects are usually mild to moderate in severity [7,8] and are reversible [8,9], whereas severe adverse effects are extremely rare [9–11]. However, patients often underestimate the risk associated with high cholesterol or heart disease and overestimate the risk posed by muscle symptoms, worrying that they may lead to serious muscle disease. Conversely, healthcare providers may underestimate the impact that muscle symptoms can have on a patient’s quality of life. The risk:benefit ratio of continuing statin therapy needs to be considered according to each patient’s individual needs in the context of the side-effects experienced.

Return to top

RELATED ARTICLES

Anti-Citrullinated Protein Antibodies as a Risk Factor for Rheumatoid Arthritis
Diane van der Woude, MD, and Tom WJ Huizinga, MD, PhD
International Journal of Advances in Rheumatology
The Economics of Rheumatoid Arthritis Management
Daniel H Solomon, MD, MPH1, and Arthur F Kavanaugh, MD2
International Journal of Advances in Rheumatology
A Question and Answer Approach to Rheumatoid Arthritis Disease Activity
Daniel Aletaha, MD, and Josef Smolen, MD
International Journal of Advances in Rheumatology
Cardiovascular Risk Factors in Rheumatoid Arthritis
Hilal Maradit Kremers, MD, MSc, Cynthia S Crowson, MS, and Sherine E Gabriel, MD, MSc
CML Rheumatology
Serum Autoantibodies in Rheumatoid Arthritis
Raimon Sanmartí, MD, Maria Victoria Hernández, MD, José A Gómez-Puerta, MD, Eduard Graell, MD, and Juan D Cañete, MD, PhD
International Journal of Advances in Rheumatology
Cardiovascular Aspects of Rheumatoid Arthritis
Michael T Nurmohamed, MD, PhD
International Journal of Advances in Rheumatology

LATEST ARTICLES